MedTrace Logo

Comparison Between HUGO RAS Robotic Platform and Da Vinci Robotic Platform

NCT06844513 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2025-02-25

No results posted yet for this study

Summary

The study is designed as a single-center, prospective, interventional, non-pharmacological, randomized, open-label, controlled trial with parallel groups. It targets patients with prostate cancer or kidney cancer who are candidates for robot-assisted surgical treatment, specifically radical prostatectomy (RP) or partial nephrectomy (PN).

Conditions

  • Prostate Cancer (Adenocarcinoma)
  • Renal Cancer

Interventions

PROCEDURE

Radical prostatectomy

Radical prostatectomy performed using the Da Vinci Xi and the HUGO RAS platform

PROCEDURE

Partial nephrectomy

partial nephrectomy (PN) using either the Da Vinci Xi platform or the HUGO™ RAS platform

Sponsors & Collaborators

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    lead OTHER

Principal Investigators

  • Eugenio Brunocilla, Prof, MD · IRCCS Azienda Ospedaliero-Universitaria di Bologna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2028-01-01
Completion
2033-03-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06844513 on ClinicalTrials.gov